News

Gene mutations are often associated with something negative, but analyzing data from ADAGIO — the largest Phase 3 clinical trial to date exploring the drug rasagiline (Azilect) in patients with early stage Parkinson’s disease — researchers identified two gene variants that determine a particularly good treatment response. Published in…

Parkinson’s disease patients in Europe will soon have to access a new treatment option for their disease, after the European Commission (EC) approved the use of  Ongentys (opicapone) — developed and marketed by Bial — as an adjunctive therapy for patients with motor fluctuation. The drug, a third-generation catechol-O-methyltransferase (COMT) inhibitor, is approved as…

A protein linked to the presence and severity of Parkinson’s has been found in urine samples from patients — opening the possibility that it can be developed into a biomarker, greatly aiding disease diagnosis and research. The finding, by researchers at the University of Alabama at Birmingham (UAB), led to two publications. In…

Sequencing the DNA of genes with known links to Parkinson’s disease revealed a previously unknown mutation in a patient with early onset disease, but while the evidence in the study pointed to the mutation as harmful, more research is needed to confirm that role. The study “Analysis of the…

Studies of the fruit fly, or Drosophila melanogaster, have shown that a protein called clueless, or clu, is associated with the mitochondrial defects observed in Parkinson’s disease patients. The study showing that clu mutations lead to muscle degeneration, “Drosophila clueless is involved in Parkin-dependent mitophagy by promoting VCP-mediated Marf…

Cynapsus Therapeutics has enrolled the final patient in its pivotal Phase 3 clinical study investigating the clinical effects of APL-130277, a fast-acting sublingual thin film for the treatment of debilitating OFF states in Parkinson’s disease (PD). Dose-titration phase results and a final evaluation of the study are expected to be released by the…

Ann Johnson, a retired veterinarian diagnosed with Parkinson’s disease (PD) almost a decade ago, usually travels 130 miles from Champaign to Chicago to be treated by Dr. Christopher Goetz at the Parkinson’s Disease and Movement Disorders Center at Rush University Medical Center. But her most recent appointment lasted less than 30…

Researchers at Johns Hopkins University School of Medicine have discovered that an enzyme known to be highly active in the brains of Parkinson’s disease patients places a molecular tag on the protein α-synuclein, causing it to aggregate and worsen its symptoms. The study, “Activation of tyrosine…

A discovery demonstrating that two Parkinson’s disease risk genes produce proteins preventing the immune system from attacking brain cells makes inherited Parkinson’s cases new candidates for autoimmune diseases. In addition to giving researchers new leads in the search for drugs that might postpone or prevent the disease, the findings might…

Cynapsus Therapeutics recently provided an update on APL-130277, its sublingual formulation of apomorphine hydrochloride or apomorphine. Apomorphine injection is the only treatment approved for acute, intermittent “off” episodes in advanced Parkinson’s disease (PD) patients. Motor symptoms such as tremor at rest, rigidity, and impaired movement or freezing, as well as difficulties with starting…